{
  "docId": "019de076-4b6e-745e-b621-2097373bdc12",
  "docSlug": "454a033dcd11e0912fc4b281c3c86d65",
  "documentTitle": "Innoviva | Results Presentation Deck | 7 slides",
  "authorId": "innoviva",
  "authorName": "Innoviva",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 7,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Clinical trial results presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4b6e-745e-b621-2097373bdc12/5",
  "deckHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12",
  "deckJsonHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12.json",
  "deckAnchorHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.52,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Microbiological cure rate at test of cure visit",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "149c004e-b0ce-4bf2-87cc-9063c00d555e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.36,
        "x": 0.6,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Zoliflodacin met the primary efficacy endpoint and was non-inferior to the comparator (point estimate 5.3% (95% confidence interval (CI): 1.4%, 8.7%)). The intent to treat analysis included all participants with a positive baseline culture for gonorrhea; those who missed the test of cure culture, were out of window, or had demonstrated microbiologic failure, were recorded as failures. When participants who had both baseline and follow up cultures were evaluated, the point estimate was reduced to 3.2% (95% CI, 1.1%, 5.1%). Clinical cure rates, as assessed by improvement in symptoms in the subset of male participants with urogenital disease, were also comparable between zoliflodacin and the comparator arms",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6c8c34c-2844-4562-8ff3-a4f8366faa8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.55,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "A high microbiological cure rate (>90% in both arms) was observed",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0575c6b-ac53-4b94-8f84-80916b1c058d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "The primary endpoint was achieved",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fb0e2d4-047b-460f-b2fc-d7485e7f08ad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "f36d0abd-2f7b-41b5-8307-2590cb9f27c7",
      "evidence": "Zoliflodacin met the primary efficacy endpoint and was non-inferior to the comparator (point estimate 5.3% (95% confidence interval (CI): 1.4%, 8.7%)).",
      "confidence": 0.8
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "6488271d-df31-43cb-9b3c-ce962b09235c",
      "evidence": "chart/bar-grouped: Microbiological cure rate at test of cure visit",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "6a75d401-e4e0-4675-b9e7-0be4bf3b7d11",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Primary endpoint achieved, secondary analyses show comparable results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cc60ccb3-7bfb-482b-bd2f-71df33588aa9",
      "evidence": "Implication of antibiotic resistance and need for new treatments",
      "position": 0,
      "objective": "What are the consequences of not adopting Zoliflodacin?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}